Sorafenib in locally advanced or metastatic breast cancer.
about
Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trialsAnti-vascular endothelial growth factor therapy in breast cancerAdvances in small-molecule drug discovery for triple-negative breast cancer.Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling.Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells.Efficacy and Safety Profile of Combining Sorafenib with Chemotherapy in Patients with HER2-Negative Advanced Breast Cancer: A Meta-analysisSorafenib: 10 years after the first pivotal trial.The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma.
P2860
Q26822432-4344C90B-FE61-4CC9-A055-C68A4502F6E4Q26999473-AC2DF990-3B66-4F39-A92D-C351FDF6FC58Q35818491-B86826FA-46F1-4FF8-8AD8-CFA853CDF13FQ37040669-EC951012-DD4C-4D7A-9F70-07CC580BC815Q37690338-600630F5-4802-4804-8A04-4ACB15CC4134Q38205442-2E09F784-4AC2-4CCF-BF82-5604DA52417DQ38544841-9C36667B-B41B-4A6A-98FB-7DB2075B6769Q39568931-91BA63CF-9712-49D8-BDC9-B8F5CB7F74D8
P2860
Sorafenib in locally advanced or metastatic breast cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Sorafenib in locally advanced or metastatic breast cancer.
@en
type
label
Sorafenib in locally advanced or metastatic breast cancer.
@en
prefLabel
Sorafenib in locally advanced or metastatic breast cancer.
@en
P2860
P1476
Sorafenib in locally advanced or metastatic breast cancer.
@en
P2093
William J Gradishar
P2860
P304
P356
10.1517/13543784.2012.689824
P407
P577
2012-05-23T00:00:00Z